Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Mesoblast within months of 3 major trial results, key regulatory decision

July 6, 2020July 6, 2020 | Tim Boreham

Health & Biotech

Health Kick: This drug developer is up 200pc following inclusion in a COVID-19 related trial

June 24, 2020June 24, 2020 | Tim Boreham

Health & Biotech

Health Kick: Cynata’s stem cell therapy could be a game changer for COVID-19 patients

June 23, 2020June 23, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Will EMVision’s links to Nanosonics set it up for similar success?

June 21, 2020June 21, 2020 | Tim Boreham

Health & Biotech

Health Kick: This stock has a clear vision for the future of contact lenses

June 10, 2020June 22, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Volpara is all about breasts but in no danger of going bust

June 5, 2020June 8, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Why Invex has all the right ingredients to possibly become a takeover target

May 24, 2020May 25, 2020 | Tim Boreham

Health & Biotech

Health Kick Podcast: Accurately measuring cognition offers massive upside to clinicians and drug makers; CGS has the tech

May 21, 2020May 21, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: A simpler device gives Atomo the upper hand in blood-based diagnostics

May 10, 2020May 10, 2020 | Tim Boreham

Health & Biotech

Health Kick Podcast: Can listed Aussie drug makers survive COVID-19?

May 7, 2020May 7, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Paradigm’s ‘ballsy’ move that landed it $35m after an FDA knock-back

April 26, 2020April 26, 2020 | Tim Boreham

Health & Biotech

Health Kick podcast: Chronic kidney disease is a worldwide health crisis, ASX-listed DXB is driving improved treatment

April 15, 2020April 15, 2020 | Tim Boreham